Shares of Bio-Techne Corp. slipped 4.01% to $48.81 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 1.01% to 6,699.38 and the Dow ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Bio-Techne (TECH) has expanded its COMET spatial biology platform with new SPYRE Focus Panels, SPYRE Amplification Kits, and updated HORIZON image analysis tools, a product move that matters for the ...

Shares of Bio-Techne Corp. TECH rallied 2.14% to $52.04 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.11% ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...